3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
45
Carcinoma, Hepatocellular
13
Osteosarcoma
8
Neoplasms
8
Sarcoma
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Sarcoma, Ewing
6
Neuroendocrine Tumors
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Non-Small-Cell Lung
6
Kidney Neoplasms
5
Thyroid Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Medullary
4
Carcinoma
4
Brain Neoplasms
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Ovarian Neoplasms
3
Melanoma
3
Endometrial Neoplasms
3
Adrenocortical Carcinoma
3
Wilms Tumor
2
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
1 year
×
Clear all
No trials found.